Evidence map›Paper›PMID 27669232›Full record

ArticleInternational journal of molecular sciences2016

Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1.

Li-Juan Ding, Yan Li, Shu-Dong Wang, Xin-Sen Wang, Fang Fang, Wei-Yao Wang, Peng Lv, Dong-Hai Zhao, Feng Wei, Ling Qi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Expression of lncRNA MSC-AS1 in hepatocellular carcinoma cell lines and its effect on proliferation, apoptosis, and migration.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Li-Juan DingDepartment of Radio-Oncology, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, China. dinglijuanjl@163.com.
Yan LiAcademy of Laboratory, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. yanli1986jl@sina.com.
Shu-Dong WangCenter of Cardiovascular Diseases, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, China. wangshudongjl@163.com.
Xin-Sen WangDepartment of Interventional Therapy, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, China. xinsenwang3@126.com.
Fang FangAcademy of Laboratory, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. fangjifang2@sina.com.
Wei-Yao WangDepartment of Pathology, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. wangweiyao2@sina.cn.
Peng LvDepartment of Pathology, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. penglv32@sina.cn.
Dong-Hai ZhaoDepartment of Pathology, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. zhaodong_hai@sina.com.
Feng WeiDepartment of Hepatobiliary and Pancreas Surgery, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, China. wei_feng@jlu.edu.cn.
Ling QiDepartment of Pathology, Jilin Medical University, No. 5 Jilin Street, Jilin 132013, China. qiling@jlmpc.cn.
Jilin Medical University · CNFirst Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common subtype of liver malignancy, and it is characterized by poor prognosis because of cancer stem cell (CSC)-mediated high postsurgical recurrence rates. Thus, targeting CSCs, or HCC cells with CSC-like properties, is an effective strategy for HCC therapy. Here, using long noncoding RNA (lncRNA) microarray analysis, we identified a novel lncRNA termed lncCAMTA1 that is increased in both liver CSCs and HCC. High lncCAMTA1 expression in HCC indicates poor clinical outcome. In vitro and in vivo functional experiments showed that overexpression of lncCAMTA1 promotes HCC cell proliferation, CSC-like properties, and tumorigenesis. Conversely, depletion of lncCAMTA1 inhibits HCC cell proliferation, CSC-like properties, and tumorigenesis. Mechanistically, we demonstrated that lncCAMTA1 physically associates with the calmodulin binding transcription activator 1 (CAMTA1) promoter, induces a repressive chromatin structure, and inhibits CAMTA1 transcription. Furthermore, CAMTA1 is required for the effects of lncCAMTA1 on HCC cell proliferation and CSC-like properties, and the expression of lncCAMTA1 and CAMTA1 is significantly negatively correlated in HCC tissues. Collectively, our study revealed the important roles and underlying molecular mechanisms of lncCAMTA1 on HCC, and suggested that lncCAMTA1 could be an effective prognostic factor and a potential therapeutic target for HCC.

Indexed as

AnimalsCalcium-Binding ProteinsCarcinoma, HepatocellularCell Line, TumorCell ProliferationChromatinDatabases, FactualDisease-Free SurvivalHep G2 CellsHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CMice, NudeNeoplastic Stem CellsCalcium-Binding ProteinsCAMTA1 protein, humanChromatinOligonucleotides, AntisenseRNA, Long NoncodingRNA, Small InterferingTrans-ActivatorsCAMTA1cancer stem cellsliver cancerlong noncoding RNAtumorigenesis

Identifiers

PMID27669232
PMCPMC5085650
OpenAlexW2521783887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.